You are here

  • Home
  • Archive
  • Volume 25, Issue 5
  • Simultaneous Modulated Accelerated Radiotherapy in Cervical Cancer With Retroperitoneal Lymph Node Metastasis After Radical Hysterectomy and Pelvic Lymphadenectomy

Article Text

Article menu
Download PDFPDF
Cervical Cancer
Simultaneous Modulated Accelerated Radiotherapy in Cervical Cancer With Retroperitoneal Lymph Node Metastasis After Radical Hysterectomy and Pelvic Lymphadenectomy
  1. Xing-lan Li, MD*,†,
  2. Zhen-yun Chen, MD‡,
  3. Yong-chun Cui, MD§ and
  4. Xui-gui Sheng, PhD*
  1. *Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, People’s Republic of China;
  2. †School of Medicine and Life Sciences, University of Jinan–Shandong Academy of Medical Sciences, Jinan, People’s Republic of China;
  3. ‡Department of Gynecologic Oncology, Linyi Tumor Hospital, Linyi, People’s Republic of China; and
  4. §Department of Education, Shandong Cancer Hospital and Institute, Jinan, People’s Republic of China.
  1. Address correspondence and reprint requests to Xiu-gui Sheng, PhD, Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, 440 Jiyan Rd, Huaiyin District, Jinan, 250117 Shandong Province, People’s Republic of China. E-mail: jnsxg@hotmail.com.

Abstract

Objective To compare the dosimetry, toxicity, and efficacy of simultaneous modulated accelerated radiotherapy (SMART) with 3-dimensional conformal radiotherapy (3DCRT) in cervical cancer with retroperitoneal lymph node metastasis after radical hysterectomy and pelvic lymphadenectomy.

Methods Total 32 patients who underwent SMART were retrospectively evaluated. Daily fractions of 2.2 to 2.4 Gy and 1.8 to 2 Gy were prescribed and delivered to gross tumor volume and clinical target volume to a total dose of 63.8 and 52.2 Gy, respectively. A 3DCRT plan was designed for the SMART group and planned to deliver the same prescribed dose. The doses of organs at risk (OARs) were compared. Thirty-six patients who received 3DCRT were used to compare the target dose, toxicities, and efficacy with 32 cases who received SMART.

Results The mean doses delivered to gross tumor volume and clinical target volume were significantly higher in the SMART group than in the 3DCRT group (63.8 vs 55.2 Gy [P < 0.01] and 52.5 vs 48.6 Gy [P < 0.01], respectively). For SMART plan, the doses of OARs were significantly lower than that of 3DCRT plans (small intestine: 25.1 vs 30.9 Gy [P < 0.01], bladder: 35.3 vs 46.3 [P < 0.01], and rectum: 31.7 vs 43.7 [P = 0.002], respectively). The patients experienced less acute and late toxicities in the SMART group (acute toxicities: enteroproctitis, P = 0.019; cystitis, P = 0.013; leukopenia, P = 0.025; late toxicities: enteroproctitis, P = 0.007; and cystitis, P = 0.026, respectively). No significant difference was found for 1-year survival (78.7% vs 67.7%, P = 0.222), but SMART group had a higher 2-year survival rate (2-year: 63.1% vs 39.1%, P = 0.029).

Conclusions Simultaneous modulated accelerated radiotherapy plans yielded higher dose to the targets and better sparing of OARs than did 3DCRT in cervical cancer with retroperitoneal lymph node metastasis after radical hysterectomy and pelvic lymphadenectomy. Simultaneous modulated accelerated radiotherapy provided better clinical outcomes than did 3DCRT. Long-term follow-up and studies involving more patients are needed to confirm our results.

  • Cervical cancer
  • Postoperative
  • Retroperitoneal lymph Node metastasis
  • Simultaneous modulated accelerated radiotherapy
  • Three-dimensional conformal radiotherapy

https://doi.org/10.1097/IGC.0000000000000426

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Xing-lan Li and Zhen-yun Chen equally contributed to this work.

    • The authors declare no conflicts of interest.